Homa Yeganegi
Chief Tech/Sci/R&D Officer chez AGENUS INC.
Profil
Homa Yeganegi est Senior Vice President & Head-Medical Affairs chez Turning Point Therapeutics, Inc. Elle a précédemment occupé le poste de vice-présidente des affaires scientifiques et médicales mondiales chez Halozyme Therapeutics, Inc. et de vice-présidente principale des affaires médicales mondiales chez Clovis Oncology, Inc. Elle est titulaire d'un diplôme de premier cycle de l'université de Téhéran et d'un diplôme d'études supérieures de l'université de Western Australia.
Postes actifs de Homa Yeganegi
| Sociétés | Poste | Début |
|---|---|---|
| AGENUS INC. | Chief Tech/Sci/R&D Officer | 20/07/2023 |
Anciens postes connus de Homa Yeganegi
| Sociétés | Poste | Fin |
|---|---|---|
| TURG POIN | Corporate Officer/Principal | - |
| CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - |
| HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Homa Yeganegi
| The University of Western Australia | Graduate Degree |
| University of Tehran | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AGENUS INC. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
